We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Statins Reduce Damage from Alzheimer's Disease

By Biotechdaily staff writers
Posted on 23 May 2002
A study has demonstrated that cholesterol-lowering drugs can block damage to neurons and blood vessels by a protein associated with Alzheimer's disease. More...
The findings were published in the April 2, 2002, issue of Atherosclerosis.

Although the risk of developing Alzheimer's has been shown to be reduced in people treated with statins, the reason is unclear. Other studies have indicated that high cholesterol or other cardiovascular conditions can increase the risk for Alzheimer's. Researchers at the University of South Florida (USF, Tampa, USA) began looking for clues that would explain the preventive action of statins. They noted that cholesterol and the A-beta protein both promote constriction of blood vessels by a similar mechanism, so they hypothesized that the same drugs that inhibit cholesterol production might affect the A-beta protein's stimulation of inflammatory substances that constrict blood vessels.

The researchers studied the effects of two statin drugs commonly used to treat elevated levels of cholesterol, lovastatin and mevastatin. They found that the A-beta protein appeared to be toxic to cultured neuronal cells, but when these neurons were treated with mevastatin, the neurotoxicity was prevented. They also observed that the statins opposed
the propensity to cause blood vessels to constrict, perhaps due to the general anti-inflammatory properties of the statins. The researchers are further testing the ability of statins to prevent or slow the course of Alzheimer's in a mouse model of the disease.

"These drugs appear to have anti-inflammatory properties, independent of their benefit in lowering cholesterol, which may help protect against dementia,” said Daniel Paris, Ph.D., first author of the study and assistant professor at the USF Roskamp Institute.


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.